The Changing Face of Prostate Diagnosis

Mr Satish Maddineni - Satish.Maddineni@srf.c.nhs.uk
Clinical Director Greater Manchester Cancer Urology Pathway Board

Fiona Lewis - Fiona.Lewis@christie.nhs.uk
Pathway Manager Greater Manchester Cancer Urology Pathway Board

Introduction

- Commonest male cancer
- 46,500 new cases in the UK each year
- Incidence 150 per 100,000
- 24% of all new cases of cancer diagnosed in men in the UK
- 11,200 men die from prostate cancer each year in UK
- Accounts for 14% of all male cancer deaths each year
- 84% of men with prostate cancer survive > 10 years
- Significant health economic burden

Background

- Greater Manchester Cancer Network – 3.2 million population
- In GM – 9000 2WW (62 day pathway) Urology referrals
- ~ 60% are for suspected prostate cancer (5,400 2WW)
- > 15% each year since 2014/15
- Challenges of 31/62 day pathway
- Challenges of meeting the patient’s needs within the pathway

Scope

To define a timely, optimised diagnostic pathway which is evidence based, innovative and deliverable in real time in today’s NHS...

mpMRI triage tool

27% can avoid biopsy
5% reduction in clinically insignificant cancers

mpMRI should become an integral part of the diagnostic pathway

Current Pathway

Overview of GM Straight to Test Pathway

Expected Outcomes

- Sepsis rate 2% from TRUS biopsy = expected reduction in ~ 20 ITU/HDU admissions
- Mp- MRI a triage tool to aid biopsy resulting in 27% of men not needing biopsy = ~1000 patients.
- Improves the detection accuracy of clinically significant cancer.
- Dramatically improve patient experience
- Improvement to 62 day performance.